Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pharmacokinetics of Afamelanotide in Erythropoietic Protoporphyria (EPP)
NCT06388642Phase 2Completed
- Sponsor
- Clinuvel Pharmaceuticals
- Start
- Mar 2024
- Primary completion
- Oct 2024
- Modality
- Peptides, Small Molecules
- Countries
- 2
01
Overview
A Phase 2 trial of Afamelanotide in erythropoietic protoporphyria (EPP), sponsored by Clinuvel Pharmaceuticals. Started Mar 2024; status: completed.
02
Drugs
Afamelanotide
03
Conditions
erythropoietic protoporphyria (EPP)
Beyond the preview
Go deeper on NCT06388642.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06388642.